Upcoming Allied Market Research
Urokinase For Injection Market

Urokinase for Injection Market

by Product Type (Urokinase Powder and Urokinase Solution) and End User (Hospitals, Ambulatory Surgical Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030

Report Code: A14915
Pages: NA
Mar 2023 | 707 Views
Author(s) : NA
Tables: NA
Charts: NA
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.



Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Urokinase For Injection Market

Request Now !

Urokinase is a thrombolytic drug commonly known as a clot-busting drug. Urokinase is a type of plasminogen activator, which is a serine protease present in humans and animals. It helps the body to produce a substance that dissolves unwanted blood clots, especially in the lungs. It is administrated slowly into the vein via intravenous route over 12 hours by using a continuous infusion pump.

Urokinase increases the risk of bleeding, which can be severe or life-threatening. Urokinase was previously used globally in healthcare markets, but now it is a monopoly. Presently only one thrombolytic drug known as tissue plasminogen activator or TPA is available for dissolving blood clots in clinics and hospitals.

Market Scope and Structure Analysis

Report Metric


Market Size Available for Years


  Base Year Considered


  Forecast Period


  Forecast Unit

  Value (USD)

  Segments Covered

  Product Type, Application, End User, and Region


COVID-19 Impact analysis

In December 2019, the World Health Organization announced the COVID-19 virus outbreak as a public health emergency. The disease has spread to over 100 countries and affected huge losses of lives around the globe. Particularly the global manufacturing, pharmaceutical, tourism, and financial markets have been hit hard. The outbreak of the pandemic has added risk factors to the already weak growth of the world economy. The descending pressure on the world economy that once showed signs of improvement in the previous period has improved again.

The negative global impacts of the COVID-19 are already there, substantially affecting the global Urokinase for injection market in the coming years, and this factor is expected to have a significantly negative impact on the revenue growth of this industry. 

Top Impacting Factors

  • Increase in cases of cardiovascular diseases, surge in geriatric populations, rise in demand for minimally invasive procedures are factors that drive the growth of the Urokinase for injection market.
  • Rise in prevalence of pulmonary embolism globally has boosted demand for blood clot-busting agents such as urokinase, which, in turn, propels the market growth. 
  • In addition, increase in healthcare expenditure, availability of skilled professionals, collaborations & partnerships between key players to facilitate drug development, rise in R&D activities to improve quality of drugs, and launch of the novel developed drug in market boost the market growth for urokinase injection.
  • Urokinase is contraindicated in hypertension patients and also in cancer patients, as urokinase elevates plasminogen activation systems, which causes tissue invasion, and, in turn, leads to metastasis and causes cancer growth. These factors restrain the growth of the global urokinase market.

Market Trends

New product launches to flourish the market

In 2018, Microbix Biosystem Inc., a biologics product manufacturer, entered into an agreement with Toreya Partners LLC for re-launch of kinlytics (urokinase) a clot busting drug in the U.S. market.

In 2019 Syner Medica LTD received approval for marketing of Syner-kinase (urokinase) in the UK by European Medical Agency.

In March 2018, Microbix Biosystems Inc., a Canadian biotechnology company commercializing novel technologies, and Cadila Healthcare Ltd. (Zydus Cadila) said that they have signed a Letter of Intent (LoI) to market the thrombolytic drug urokinase in the North American market.

Surge in usage due to cardiovascular disorders

Cardiovascular diseases are gradually becoming the leading cause of morbidity and mortality globally. Cardiovascular disorders are on rise worldwide due to raised blood lipids, obesity, alcohol abuse, hypertension, diabetes, and age-related risks. The use of classical anticoagulant and antiplatelet therapies combined with surgical intervention helped to clear blood clots during the inceptive years. However, the discovery of streptokinase and urokinase steered the way of using these enzymes as thrombolytic agents to degrade the fibrin network with an issue of systemic hemorrhage.

Rise in prevalence of pulmonary embolism globally has boosted the demand for blood clot-busting agents such as urokinase. For instance, according to the National Library of Health in 2018, pulmonary embolism has a high prevalence globally with 10 million cases per year. Moreover, usage of urokinase in the treatment of cardiovascular disease is driving demand for blood clot-busting agents such as urokinase injection.

Key Benefits of the Report

  • This study presents the analytical depiction of the urokinase for injection market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the urokinase for injection market share.
  • The current market is quantitatively analyzed from 2020 to 2030 to highlight the Urokinase for injection market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Urokinase for Injection Report

  • Who are the leading market players active in the urokinase for injection market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What future projections would help in taking further strategic steps?
  • What is "urokinase for injection"?
  • What is "urokinase for injection" market prediction in the future?
  • Who are the leading global players in the "urokinase for injection" market?
  • What are the current trends and predicted trends?

Urokinase for Injection Market Report Highlights

Aspects Details
By Product Type
  • Urokinase Powder
  • Urokinase Solution
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players NDPharm,, Wanhua Biochem,, Jiangxi Haoran Bio-Pharma,, Jiangsu Aidea Pharmaceutical

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Urokinase For Injection Market

Start reading.
This Report and over 19,665+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,870
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers